The Siteman Cancer Center Bioinformatics Core is currently in collaboration with a study of GAML PPG defining all the genetic alterations that occur in adult Acute Myelogenous Leukemia (AML) cells, and to define the importance of these mutations for disease susceptibility, initiation, progression, relapse, and resistance. The short-term goal is to define the most frequently occurring mutations that affect clinical outcomes, since these are the ones most likely to have an impact on therapy. We will use this information to create molecular diagnostic tools for disease stratification, and identify candidate genes for targeted therapeutics. The identification of the mutations that occur in adult AML genomes will contribute greatly to our understanding of the pathogenesis of this disease.